Literature DB >> 19293056

Results of R0 surgery with D2 lymphadenectomy for the treatment of localised gastric cancer.

A Díaz de Liaño1, C Yárnoz, C Artieda, R Aguilar, S Viana, A Artajona, H Ortiz.   

Abstract

INTRODUCTION: Surgical excision is the best therapeutic option for gastric cancer, provided it is performed with curative intent as R0 surgery. And, according to many authors, D2 lymphadenectomy may be performed with acceptable morbidity and mortality rates.
MATERIALS AND METHODS: A prospective study was conducted on a series of 126 consecutive cases of gastric cancer treated with gastrectomy and D2 lymphadenectomy. A R0 resection was done in 99 cases (78.6%).
RESULTS: Total gastrectomy was performed in 70 patients and subtotal gastrectomy in 29. The mean number of lymph nodes removed was 32.5 per patient. Suture dehiscence occurred in 3 patients (in one of them in the esophago-jejunal anastomosis). Hospital mortality was 2%. Twenty-six recurrences were detected after a median follow-up of 73.6 months. Five-year actuarial survival was 65%. Five-year survival of patients with positive lymph nodes at the N2 level was 26.5%.
CONCLUSIONS: Gastrectomy with D2 lymphadenectomy may be performed with low morbidity and mortality. R0 resection allows acceptable survival rates to be achieved. There is even a group of patients with invaded lymph nodes at the N2 level surviving at 5 years. It appears to be very important that this surgery is performed by specialised surgeons.

Entities:  

Mesh:

Year:  2009        PMID: 19293056     DOI: 10.1007/s12094-009-0335-9

Source DB:  PubMed          Journal:  Clin Transl Oncol        ISSN: 1699-048X            Impact factor:   3.405


  29 in total

1.  Influence of overweight on surgical complications for gastric cancer: results from a randomized control trial comparing D2 and extended para-aortic D3 lymphadenectomy (JCOG9501).

Authors:  Toshimasa Tsujinaka; Mitsuru Sasako; Seiichiro Yamamoto; Takeshi Sano; Yukinori Kurokawa; Atsushi Nashimoto; Akira Kurita; Hitoshi Katai; Toshio Shimizu; Hiroshi Furukawa; Satoru Inoue; Masahiro Hiratsuka; Taira Kinoshita; Kuniyoshi Arai; Yoshitaka Yamamura
Journal:  Ann Surg Oncol       Date:  2006-12-05       Impact factor: 5.344

2.  Risk factors for surgical treatment in the Dutch Gastric Cancer Trial.

Authors:  M Sasako
Journal:  Br J Surg       Date:  1997-11       Impact factor: 6.939

3.  Total versus subtotal gastrectomy: surgical morbidity and mortality rates in a multicenter Italian randomized trial. The Italian Gastrointestinal Tumor Study Group.

Authors:  F Bozzetti; E Marubini; G Bonfanti; R Miceli; C Piano; N Crose; L Gennari
Journal:  Ann Surg       Date:  1997-11       Impact factor: 12.969

4.  Postoperative morbidity and mortality after D1 and D2 resections for gastric cancer: preliminary results of the MRC randomised controlled surgical trial. The Surgical Cooperative Group.

Authors:  A Cuschieri; P Fayers; J Fielding; J Craven; J Bancewicz; V Joypaul; P Cook
Journal:  Lancet       Date:  1996-04-13       Impact factor: 79.321

5.  Extended lymph-node dissection for gastric cancer.

Authors:  J J Bonenkamp; J Hermans; M Sasako; C J van de Velde; K Welvaart; I Songun; S Meyer; J T Plukker; P Van Elk; H Obertop; D J Gouma; J J van Lanschot; C W Taat; P W de Graaf; M F von Meyenfeldt; H Tilanus
Journal:  N Engl J Med       Date:  1999-03-25       Impact factor: 91.245

6.  A prospective randomized study comparing D2 total gastrectomy versus D2 total gastrectomy plus splenectomy in 187 patients with gastric carcinoma.

Authors:  Attila Csendes; Patricio Burdiles; Jorge Rojas; Italo Braghetto; Juan Carlos Diaz; Fernando Maluenda
Journal:  Surgery       Date:  2002-04       Impact factor: 3.982

7.  Extended local resection for advanced gastric cancer: increased survival versus increased morbidity.

Authors:  Robert C G Martin; David P Jaques; Murray F Brennan; Martin Karpeh
Journal:  Ann Surg       Date:  2002-08       Impact factor: 12.969

8.  Gastric cancer surgery: morbidity and mortality results from a prospective randomized controlled trial comparing D2 and extended para-aortic lymphadenectomy--Japan Clinical Oncology Group study 9501.

Authors:  Takeshi Sano; Mitsuru Sasako; Seiichiro Yamamoto; Atsushi Nashimoto; Akira Kurita; Masahiro Hiratsuka; Toshimasa Tsujinaka; Taira Kinoshita; Kuniyoshi Arai; Yoshitaka Yamamura; Kunio Okajima
Journal:  J Clin Oncol       Date:  2004-06-15       Impact factor: 44.544

Review 9.  Epidemiology of gastric cancer.

Authors:  Katherine D Crew; Alfred I Neugut
Journal:  World J Gastroenterol       Date:  2006-01-21       Impact factor: 5.742

10.  Morbidity and mortality after D1 and D2 gastrectomy for cancer: interim analysis of the Italian Gastric Cancer Study Group (IGCSG) randomised surgical trial.

Authors:  M Degiuli; M Sasako; M Calgaro; M Garino; F Rebecchi; M Mineccia; D Scaglione; D Andreone; A Ponti; F Calvo
Journal:  Eur J Surg Oncol       Date:  2004-04       Impact factor: 4.424

View more
  5 in total

1.  Problems faced by evidence-based medicine in evaluating lymphadenectomy for gastric cancer.

Authors:  Giuseppe Verlato; Simone Giacopuzzi; Maria Bencivenga; Paolo Morgagni; Giovanni De Manzoni
Journal:  World J Gastroenterol       Date:  2014-09-28       Impact factor: 5.742

2.  N stages of the seventh edition of TNM Classification are the most intensive variables for predictions of the overall survival of gastric cancer patients who underwent limited lymphadenectomy.

Authors:  Jingyu Deng; Rupeng Zhang; Yuan Pan; Baogui Wang; Liangliang Wu; Xishan Hao; Han Liang
Journal:  Tumour Biol       Date:  2013-11-29

Review 3.  Gastric cancer: Current status of lymph node dissection.

Authors:  Maurizio Degiuli; Giovanni De Manzoni; Alberto Di Leo; Domenico D'Ugo; Erica Galasso; Daniele Marrelli; Roberto Petrioli; Karol Polom; Franco Roviello; Francesco Santullo; Mario Morino
Journal:  World J Gastroenterol       Date:  2016-03-14       Impact factor: 5.742

Review 4.  Clinical significance of lymph node metastasis in gastric cancer.

Authors:  Jing-Yu Deng; Han Liang
Journal:  World J Gastroenterol       Date:  2014-04-14       Impact factor: 5.742

5.  Clinicopathological characteristics and optimal management for esophagogastric junctional cancer; a single center retrospective cohort study.

Authors:  Hiroaki Ito; Haruhiro Inoue; Noriko Odaka; Hitoshi Satodate; Michitaka Suzuki; Shumpei Mukai; Yusuke Takehara; Hiroyuki Kida; Shin-Ei Kudo
Journal:  J Exp Clin Cancer Res       Date:  2013-01-07
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.